Overview

HAIC Combined With Lenvatinib and Sintilimab for Hepatocellular Carcinoma With PVTT

Status:
Recruiting
Trial end date:
2022-12-30
Target enrollment:
Participant gender:
Summary
This study intends to evaluate the efficacy and safety of hepatic arterial infusion chemotherapy of oxaliplatin, 5-fluorouracil and leucovorin plus lenvatinib and Sintilimab for patients hepatocellular carcinoma and portal vein tumor thrombus.
Phase:
N/A
Details
Lead Sponsor:
Sun Yat-sen University
Collaborator:
Second Affiliated Hospital of Guangzhou Medical University
Treatments:
Lenvatinib